Skip to main content
. 2013 Sep 11;8(9):e74654. doi: 10.1371/journal.pone.0074654

Figure 6. Tumor cell derived MVs promote the proliferative impact of anti-CD3/CD28 mAb stimulation on PBMC.

Figure 6

Freshly isolated human PBMC were kept for 3 days in the presence of CD3/CD28, CD3/CD28/MVs and MVs alone. As control untreated cells were used. For the last 14-18 h of cell culture the BrdU compound (Roche) was added. Then the cell proliferation assay was performed according to the manufacturer’s protocol. Experiments were performed in triplicates and results presented are expressed as means of OD 450 nm ± SD. The data show one representative result of four independent repeats of the experiment. The difference between the control group and the CD3/CD28 and CD3/CD28/MVs treated groups as well as the CD3/CD28 and CD3/CD28/MVs treated groups were determined by student t-test (*p≤0.005 and **p≤0.0065, respectively; n=3).